Neurology Advisor spoke with Klaus Schmierer, MBBS, PhD, to discuss new evidence suggesting a protective antibody response following vaccination in patients with MS taking MAVENCLAD.
Investigators conducted a survey to assess the incidence of COVID-19 in patients with multiple sclerosis as well as the influence of their comorbidities and treatments on outcomes.
The cognitive effects of multiple sclerosis are often associated with later stages of the disease. However, there may be some indicators of its involvement in patients with early stages. Understanding these factors — some of which are psychological and some of which are clinical — could help with treating and monitoring patients.
A team of researchers assessed the Secondary Progressive Risk Score (SP-RiSc) on its ability to identify patients at elevated risk of secondary progressive MS.
The study found worsening disease in those with thinning in the ganglion cell layer plus inner plexiform layer plus peripapillary retinal nerve fibre layer.
To determine the effectiveness of the Risk of Ambulatory Disability (RoAD) score, study researchers evaluated the prognosis of patients with relapsing-remitting MS.
In an abstract presented at AAN 2021, researchers described the effect of disease-modifying therapies on COVID-19 severity in patients with COVID-19 and multiple sclerosis.
Study researchers sought address the lacking data on the spatial characteristics of lesions affecting the MLF in patients with MS or stroke, the most common pathophysiologies of internuclear ophthalmoplegia.
